These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27992714)

  • 21. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.
    Jiao L; Liu X
    Science; 2015 Oct; 350(6258):aac4383. PubMed ID: 26472914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of selective activators of PRC2 mutant EED-I363M.
    Suh JL; Barnash KD; Abramyan TM; Li F; The J; Engelberg IA; Vedadi M; Brown PJ; Kireev DB; Arrowsmith CH; James LI; Frye SV
    Sci Rep; 2019 Apr; 9(1):6524. PubMed ID: 31024026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
    Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
    Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
    Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R
    Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of automethylated PRC2 by dimerization on chromatin.
    Sauer PV; Pavlenko E; Cookis T; Zirden LC; Renn J; Singhal A; Hunold P; Hoehne MN; van Ray O; Hänsel-Hertsch R; Sanbonmatsu KY; Nogales E; Poepsel S
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PALI1 facilitates DNA and nucleosome binding by PRC2 and triggers an allosteric activation of catalysis.
    Zhang Q; Agius SC; Flanigan SF; Uckelmann M; Levina V; Owen BM; Davidovich C
    Nat Commun; 2021 Jul; 12(1):4592. PubMed ID: 34321472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategy for "detoxification" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2.
    Brown ZZ; Müller MM; Jain SU; Allis CD; Lewis PW; Muir TW
    J Am Chem Soc; 2014 Oct; 136(39):13498-501. PubMed ID: 25180930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
    Bao Q; Kumar A; Wu D; Zhou J
    Drug Discov Today; 2024 Jun; 29(6):103986. PubMed ID: 38642703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
    Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin-induced acute kidney injury.
    Yu C; Li T; Li J; Cui B; Liu N; Bayliss G; Zhuang S
    J Cell Mol Med; 2022 Jul; 26(14):4061-4075. PubMed ID: 35734954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators.
    Danishuddin ; Subbarao N; Faheem M; Khan SN
    Drug Discov Today; 2019 Jan; 24(1):179-188. PubMed ID: 30031878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells.
    Koppens MA; Bounova G; Gargiulo G; Tanger E; Janssen H; Cornelissen-Steijger P; Blom M; Song JY; Wessels LF; van Lohuizen M
    Gastroenterology; 2016 Oct; 151(4):684-697.e12. PubMed ID: 27342214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
    Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
    Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of SET/EED dual binders as innovative PRC2 inhibitors.
    Catalano R; Maruca A; Rocca R; Tassone P; Panzarella G; Costa G; Ortuso F; Alcaro S
    Future Med Chem; 2022 May; 14(9):609-621. PubMed ID: 35348013
    [No Abstract]   [Full Text] [Related]  

  • 36. Bending and looping of long DNA by Polycomb repressive complex 2 revealed by AFM imaging in liquid.
    Heenan PR; Wang X; Gooding AR; Cech TR; Perkins TT
    Nucleic Acids Res; 2020 Apr; 48(6):2969-2981. PubMed ID: 32043141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
    Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
    Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
    Simon JA; Lange CA
    Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
    Tiffen J; Gallagher SJ; Hersey P
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):21-30. PubMed ID: 24912396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.